Phase II Multicenter Study of Antroquinonol in Patients with Stage IV Non-Small Cell Lung Cancer Who Have Failed at Least Two Lines of Anti-Cancer Therapy

Authors: Ching-Liang Ho, David S. Ettinger, Pei-Ni Chen, Howard Cheng, Wu-Che Wen, Shang-Yin Wu, Thierry Marie Jahan, Mary J. Fidler, Bradley Walter Lash, Igor I. Rybkin, and Natalie Stanton

Journal: Journal of Clinical Oncology

Study Design: Phase II multicenter study

Participants: 31 patients with stage IV non-squamous NSCLC who have failed at least two lines of anti-cancer therapy

Intervention: Antroquinonol 600mg per day

Outcome Measures:

• Progression-free survival (PFS) at week 12
• Disease control rate (DCR)
• Overall survival (OS)
• Toxicities

Summary:

This phase II study evaluated the efficacy of antroquinonol, a compound derived from Antrodia camphorata, in patients with stage IV NSCLC who had failed at least two prior anti-cancer therapies. The study included 31 patients, with 15 being KRAS-positive and 15 KRAS-negative. The median PFS for patients with two prior chemotherapy regimens was 22.9 weeks, while for those with more than two prior regimens, it was 11.9 weeks. The overall DCR was 72.7%, with 100% in KRAS-negative and 50% in KRAS-positive patients. No systemic toxicities were observed. The study concluded that antroquinonol monotherapy resulted in higher DCR, longer PFS, and longer OS compared with historical data, suggesting its potential as a treatment option for this patient population.   Sources and related content